Why Analysts are Rating Alkermes (ALKS) a Buy

Alkermes plc (NASDAQ:ALKS) is one of the most promising mid-cap healthcare stocks under $50.

At the close of play on December 19, the consensus ratings remain bullish for Alkermes plc (NASDAQ:ALKS). The stock has been covered by 15 analysts, of which 11 assigned it Buy ratings and the remaining 4 were Holds. As per analyst estimates, the forecasted median 1-year price target for the stock is $46.17 a share, resulting in 62.3% upside potential at the prevailing prices.

Likoper/Shutterstock.com

On December 3, the company Chairman and CEO, Richard Pops, presented at the Evercore 8th Annual Healthcare Conference. He described 2025 as a truly transformational year for the business. Apart from positive NT1 and NT2 data, he also spoke about the company’s aggressive pursuits within the hypersomnolence market. Alkermes (NASDAQ:ALKS) plans to acquire Avadel, a profitable company with a circa $275 million topline. Pops linked this strategic acquisition with their planned launch of alixorexton, an oral drug for treating complex sleep disorders.

On December 5, Piper Sandler analyst David Amsellem also reaffirmed his bullish view of Alkermes (NASDAQ:ALKS). He gave a Buy call for the stock with a price target of $45. As per his estimates, the stock currently offers more than 58% upside potential to investors.

Alkermes (NASDAQ:ALKS) is a biopharmaceutical company that develops and commercializes innovative medicines to address neurological disorders. The company leverages its proprietary technologies for formulations that cater to individuals with psychiatric conditions. They also directly purchase active drugs from third parties.

While we acknowledge the risk and potential of ALKS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALKS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.